Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Prognostic Significance of Cyclin E and p27 in Stage 1 Non-Small Cell Lung Cancer

제1병기 비소세포폐암에서 Cyclin E와 p27의 발현과 예후

  • 조봉균 (고신대하교 의학부 흉부외과학교실) ;
  • 조성래 (고신대하교 의학부 흉부외과학교실) ;
  • 천봉권 (고신대학교 의학부 해부병리과)
  • Published : 2003.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Cyclin I plays a pivotal role in the regulation of G1-S transition and could consequently be a deregulated molecule in tumors. The activity of the cdk2-cyclin E complex is increased by degradation of cdk inhibitor p27kip1. Little is known about the expression and prognostic significance of cyclin E and p27 in non-small cell lung cancer(NSCLC). Material and Method: The expression of cyclin E and p27 in eighty-one cases of resected stage I NSCLC tissues and its relation to major clinico-pathological factors, including histology, differentiation, size of tumor, pleural invasion and survival rate were studied and analyzed. Immunohistochemical analysis with monoclonal antibodies specific for cyclin E and p27 were performed by ABC method. Result: Expression rates of cyclin E and p27 in stage I NSCLC tissues were 29.6% and 28.4% respectively. Cyclin E was expressed higher in cases of pleural invasion(p=0.04), and p27 was expressed higher in diameter of tumor less than 3cm(p=0.015). The 5-years survival rate was lower in cases of Positive expression of cyclin E than in cases of negative expression of cyclin E(44.4% vs 68.2%, p=0.015), and the 5-years survival rate was 72.2% in positive expression of p27 and 56.2% in negative expression of p27(p=0.09). The 5-years survival rate was higher in negative expression of cyclin E and positive expression of p27 than in cases of positive expression of cyclin I and negative expression of p27 (73.5% vs 36.3%, p=0.0029). In multivariate analysis, expression of cyclin I was an unfavorable prognostic factor(RR=3.578, p=0.006) and p27 was a favorable prognostic factor(RR=0.183, p=0.019) independently. Conclusion: Cyclin E and p27 may play a pivotal role for the biological behavior of stage I NSCLC, so that the expressions of cyclin I and p27 nay be new prognostic markers.

Cyclin E는 Gl-S기로의 이행을 조절하는데 매우 중요한 역할을 하는데, 세포주기 중 $G_{0}$ / $G_{1}$기로부터 S기로의 이행의 조절이상은 종양형성에 중요한 요소로 알려져 있으므로, 여러 종류의 악성종양에서 cyclin E의 발현은 종양의 생물학적 양상과 관련되어 보고되고 있다. 또 cdk2-cyclin E 복합체의 활성도는 cdk 억제인자인 p27$^{kip1}$의 분해에 의하여 증가한다. 그러나 비소세포폐암에서 cyclin E와 p27의 발현에 관한 연구는 매우 드물다. 대상 및 방법: 81례의 절제된 제1병기 비소세포폐암 조직을 이용하여 cyclin E와 p27의 발현율을 조사하고, 조직학적 유형, 분화도, 종양의 크기, 늑막의 침범 여부, 생존율과의 상호관계를 비교 분석하였다. Cyclin E와 p27의 발현은 특이한 단클론 항체를 이용하여 ABC법으로 면역조직화학염색을 시행하였고, 생존율은 Kaplan-Meier법을 이용하였다. 결과: 제1병기 비소세포폐암에서 cyclin E와 p27의 발현율은 각각 29.6%,28.4%였다. Cyclin E는 늑막 침범례에서, p27은 종양의 직경이 3cm 이하인 경우에 각각 높은 발현율을 보였다(p=0.04, p=0.015). Cyclin E의 발현군의 5년 생존율은 44.4%로, 미 발현군 68.2%에 비해 낮았으며(p=0.015), p27의 발현군의 5년 생존율은 72.2%로, 미 발현군 56.2%에 비해 높은 경향을 보였다(p=0.09). Cyclin E가 발현되지 않고 p27이 발현되는 군의 5년 생존율은 73.5%로, cyclin E가 발현되고 p27이 발현되지 않는 군 36.3%에 비해 높게 나타났다(p=0.0029). 다변량 분석상 cyclin E은 불량한 예후를(RR=3.578, p=0.006), p27은 양호한 예후를 시사하는 독립적인 인자였다(RR=0.183, p=0.009). 결론: 제1병기 비소세포폐암에서 cyclin E의 발현은 불량한 예후를, p27은 양호한 예후를 나타내는 독립적인 예후인자가 될 수 있음을 확인하였다.

Keywords

References

  1. Cancer v.77 The National Cancer Data Base report on lung cancer Fry,W.A.;Menck,H.R.;Winchester,D.P. https://doi.org/10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z
  2. Principles and Practice of Oncology(5th ed.) Minna,J.D.;Sekido,Y.;Fong,K.M.;Gazder,A.F.
  3. Science v.274 Cancer cell cycles Sherr,C.J.
  4. Prog Cell Cycle Res v.1 The role of RB in cell cycle control Hatakeyama,M.;Weinberg,R.A.
  5. Curr Opin Cell Biol v.9 The restriction point and control of cell proliferation Planas-Silva,M.D.;Weinberg,R.A. https://doi.org/10.1016/S0955-0674(97)80076-2
  6. Nature v.9 Principles of CDK regulation Morgan,D.O.
  7. Genes Dev v.9 Inhibitors of mammalian G1 cyclin-dependent kinases Sherr,C.J.;Roberts,J.M. https://doi.org/10.1101/gad.9.10.1149
  8. J Cell Sci Suppl v.18 G1 control in mammalian cells Reed,S.I.;Bailly,E.;Dulic,V.;Hengst,L.;Resnitzky,D.;Slingerland,J.
  9. Oncogene v.9 CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinet subset of the cyclin-dependent kinases that associate with cyclin D1 Bates,S.;Bonetta,L.;MacAllan,D.(et al.)
  10. Mol Cell Biol v.14 D-type cyclin-dependent kinase activity in mammalian cells Matsushime,H.;Quelle,D.E.;Shurtleff,S.A.(et al.) https://doi.org/10.1128/MCB.14.3.2066
  11. Mol Cell Biol v.14 Identification of G1 kinase activity for cdk6, a novel cyclin D partner Meyerson,M.;Harlow,E. https://doi.org/10.1128/MCB.14.3.2077
  12. Cell v.71 D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA Xiong,Y.;Zhang,H.;Beach,D. https://doi.org/10.1016/0092-8674(92)90518-H
  13. Science v.257 Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle Koff,A.;Giordano,A.;Desai,D.(et al.) https://doi.org/10.1126/science.1388288
  14. Cancer Res v.54 Cyclin E, a potential prognostic marker for breast cancer Keyomarsi,K.;O'Leary,N.;Molnar,G.(et al.)
  15. Genes Dev v.8 p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest Polyak,K.;Kato,J.Y.;Solomon,M.J.(et al.) https://doi.org/10.1101/gad.8.1.9
  16. Chest v.6 Revisions in the International System for Staging Lung Cancer Mountain,C.F.
  17. Histologic Typing Lung and Pleural Tumors v.6 Collaborators from 14 countries Travis,W.D.;Colby,T.V.;Corrin,B.;Shimosato,Y.;Brambilla,E.;Mishina,T.;Dosaka-Akita,H.;Hommura,F.(et al.)
  18. Clin Cancer Res v.6 Expression, a potential porgnostic marker for non-small cell lung cancers
  19. Oncogene v.13 Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation Langenfeld,J.;Lonardo,F.;Kiyokawa,H.(et al.)
  20. Cancer Res v.59 Overexpression of cyclins D1 and E is frequent in bronchial preneplasia and precedes squamous cell carcinoma development Lonardo,F.;Rusch,V.;Langenfeld,J.;Dmitrovsky,E.;Klimstra,D.S.
  21. Oncogene v.11 Deregulation of cyclin E in breast cancer Keyomarsi,K.;Conte,D.Jr;Toyofuku,W.;Fox,M.P.
  22. Cancer Res v.61 Cylin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer Muller-Tidow,C.;Metzger,R.;Kugler,K.(et al.)
  23. Cancer Res v.54 Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines Gong,J.;Ardelt,B.;Traganos,F.;Darzynkiewicz,Z.
  24. Br J Cancer v.80 Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome Mishina,T.;Dosaka-Akita,H.;Kinoshita,I.(et al.) https://doi.org/10.1038/sj.bjc.6690500
  25. Lung Cancer v.26 The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens Ishihara,S.;Minato,K.;Hoshino,H.(et al.) https://doi.org/10.1016/S0169-5002(99)00085-9
  26. Jpn J Cancer Res v.88 Reduced expression of cyclin-dependent kinase inhibitor p27Kipl is associated with advanced stage and invasiveness of gastric carcinomas Yasui,W.;Kudo,Y.;Semba,S.;Yokozaki,H.;Tahara,E. https://doi.org/10.1111/j.1349-7006.1997.tb00428.x
  27. Blood v.92 Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications Erlanson,M.;Portin,C.;Linderholm,B.(et al.)